- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr David Blumenthal Weighs in on the Effect of King v. Burwell Decision
On March 4 the Supreme Court will hear arguments in the case of King v. Burwell, which determines the fate of subsidies in the 34 federally facilitated marketplaces, and David Blumenthal, MD, chief executive officer of The Commonwealth Fund, outlined the potentially catastrophic effects if the Court were to side with the plaintiffs.
On March 4 the Supreme Court will hear arguments in the case of King v. Burwell, which determines the fate of subsidies in the 34 federally facilitated marketplaces, and David Blumenthal, MD, president of The Commonwealth Fund, outlined the potentially catastrophic effects if the Court were to side with the plaintiffs.
A ruling that strikes down subsidies for individuals on the federal marketplace would not only affect those who were relying on the assistance for health insurance, he explained. Some providers, particularly safety net providers, would suffer financial losses that would make it difficult to treat all patients, not just those directly affected by the court ruling.
“We see lots of negative side effects and certainly are concerned that some of the very important gains that have been made under the Affordable Care Act—with respect to access to care, reduction of medical debt, reduction of financial barriers to care—that some of those very important gains would be lost,” Dr Blumenthal said.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
